Cell-Based Therapy for Cerebral Palsy: A Puzzle in Progress
نویسندگان
1 R&D Department, Royan Stem Cell Technology Company, Tehran, Iran
2 Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Children’s Medical Center, Pediatrics Center of Excellence, Tehran, Iran
4 Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
5 R&D Department, Royan Stem Cell Technology Company, Tehran, Iran
6 Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
7 Pediatric Neurology Division, Children’s Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran
8 Pediatric Cell, Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran
doi
10.22074/cellj.2024.2032098.1600چکیده
Cell-based therapy has shown promising outcomes in the treatment of cerebral palsy (CP). However, there is noconsensus on a standard therapeutic protocol regarding the source of cells, optimal cell dose, timing and frequencyof cell injections, route of administration, or the use of combination therapy. This lack of consensus necessitates acomprehensive investigation to clarify these crucial yet undefined factors in cell-based therapy for CP patients. In thiscommentary, we discuss and compare the trends in Gross Motor Function Measure-66 following intrathecal injectionof umbilical cord blood mononuclear cells (UCB-MNCs) and umbilical cord tissue mesenchymal stromal cells (UCTMSCs)in children with CP. Our study revealed that MNC injections led to earlier improvements in gross motor function,whereas MSC applications resulted in more sustainable changes. These findings provide key insights into the efficacyof different cell types, which will be beneficial for future studies and for refining cell-based therapy protocols for CPtreatment.
